G-CSF and GM-CSF in clinical trials

Area of Science:

• Biotechnology
• Hematology
• Immunology

Background:

• Hematopoietic growth factors have been successfully purified, cloned, and produced using recombinant DNA technology in bacteria and yeast.
• Several key growth factors, including erythropoietin, granulocyte-macrophage colony-stimulating factor (GM-CSF), granulocyte colony-stimulating factor (G-CSF), macrophage colony-stimulating factor (M-CSF), and multi-colony-stimulating factor (multi-CSF or interleukin 3), are under clinical investigation.

Purpose of the Study:

• To evaluate the potential of hematopoietic growth factors to enhance white blood cell recovery and function.
• To assess the efficacy of these factors in patients undergoing cancer therapy, bone marrow transplantation, and those with acquired immune deficiency syndromes (AIDS) and myelodysplastic syndromes.

Main Methods:

• Clinical trials, including Phase I, II, and III studies, have been conducted.
• These trials involve patients receiving chemotherapy, undergoing bone marrow transplantation, and individuals with AIDS or myelodysplastic syndromes.

Main Results:

• Published results from Phase I and II trials indicate potential benefits in restoring leukocyte numbers and competence.
• Growth factors appear likely to enhance the recovery and function of circulating white cells, particularly after standard- and high-dose cancer therapy with marrow transplant.

Conclusions:

• Hematopoietic growth factors show promise in improving outcomes for patients with compromised immune systems and those undergoing intensive cancer treatments.
• Ongoing Phase III studies are expected to provide definitive data on the efficacy and safety of these therapeutic agents.